Filter posts

Kentucky Officials Expose PBMs for Gaming the System

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet …

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the …

Health Care in Focus as President Trump Addresses the Nation

In his State of the Union address, President Trump described the need to rein in …

Greenwood Shines Spotlight on Insurance Industry Rip-off

Writing for The Hill, BIO’s President and CEO Jim Greenwood shined a spotlight on a …

The Right Way to Address Prescription Drug Costs

Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City …

Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio

During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks …

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate …

Medical Research from Mars Can Fail Patients from Venus

Historically, federal dollars inadvertently flowed to medical research with a disproportionate focus on men’s health. …

Innovative Policies Drive the Biobased Economy

This year not only marks the 25th anniversary of BIO, but this year we also …

My Pledge at World Congress: BIO Will Lead on Gene Editing

This year marks the 15th anniversary of BIO’s World Congress on Industrial Biotechnology, as well …